The ASX Blue Chip Portfolio holds Sonic Healthcare. The company lodged its FY26 full year result with the ASX on Wednesday 20 August 2026, covering the twelve months to 30 June 2026.
Revenue rose 13% to A$10.87 billion. Organic growth contributed 5%, with acquisitions supplying the rest, chiefly the LADR Laboratory Group in Germany alongside the Swiss laboratory businesses. Underlying EBITDA grew 11% to A$1,933 million and underlying net profit rose 17% to A$621 million. Underlying earnings per share reached 125.6 cents, up 14%, against analyst forecasts closer to 141 cents. Statutory net profit of A$608.3 million landed near consensus. The EBITDA margin narrowed to 17.8% from 18.2%.
The board declared a final dividend of 63 cents, taking the full year payout to A$1.08, one cent above FY25.
| Metric | Actual | Comparison |
| Revenue | A$10.87bn | +13% on FY25 |
| Underlying EBITDA | A$1,933m | +11% on FY25 |
| Underlying NPAT | A$621m | +17% on FY25 |
| Underlying EPS | 125.6c | consensus approx. 141c |
| Total dividend | A$1.08 | A$1.07 in FY25 |
| FY27 EBITDA guidance | A$1.95bn to A$2.03bn | A$1,933m in FY26 |
Management guided FY27 EBITDA to a range of A$1.95 billion to A$2.03 billion on a constant currency basis, excluding roughly A$30 million of IT transformation spending. The midpoint implies low single digit growth. Sonic flagged Swiss fee reductions that remove about 3% of revenue in that market, integration delays and labour costs in the United Kingdom despite 17% organic revenue growth there, and flat organic growth in the United States, where an operating review continues into FY27. Interest expense climbed 18.6% as acquisition debt accumulated. Gearing finished at 25.9% and operating cash flow rose 8.4% to A$1.405 billion. The German LADR business delivered A$59.1 million of profit after tax in its first full contribution.
Chief Executive Dr Jim Newcombe told the earnings call: “We delivered solid financial results in FY 2026, achieving our EBITDA guidance for the year on an underlying basis.” The company also pointed to its digital and AI transformation programs and to the sale and leaseback of its Brisbane hub laboratory, which completed during the year.
The FY27 outlook drove the day’s trade. Shares closed at A$21.38 on 20 August, down 9.25% from the prior close of A$23.56, moving toward the lower end of a 52 week range that begins at A$18.26. Sonic now runs laboratory and imaging operations across nine countries, serving more than 140 million patients a year with about 47,000 staff.
